Handelsavisen
prelaunch
Companies ›Healthcare ›NOIN.BO
NO
NOIN.BO — BSE (India) Pharmaceuticals

Novartis India Ltd

$1 488,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
LatestChrysCapital takes control of Novartis India in ₹1,446 crore deal
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
2,42 %
Op margin
25,3 %
ROE
12,8 %
Net margin
28,3 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company maintains a strong liquidity position, with a current ratio of 5.25 and cash and equivalents of ₹490 million, indicating a robust ability to meet short-term obligations. The low debt-to-equity ratio of 0.01 suggests a conservative capital structure, with minimal reliance on long-term debt. Profitability metrics show a return on equity (ROE) of 12.85% and a return on assets (ROA) of 10.65%, both exceeding the typical thresholds for the pharmaceutical industry. These figures reflect efficient use of equity and assets to generate returns, aligning with the company's focus on high-margin prescription drug sales. Geographically, the company's revenue is concentrated in India, with no disclosed international segments. This concentration may expose the business to regulatory and macroeconomic risks specific to the Indian market, though the company's strong domestic presence and brand recognition mitigate some of these concerns. The company's growth trajectory is supported by a consistent revenue base of ₹3.56 billion and a net income of ₹1.01 billion. While no specific growth rates are provided, the operating cash flow of ₹745.7 million and free cash flow of ₹413.6 million

Business. Novartis India Ltd (NOIN.BO) is a pharmaceutical company headquartered in India that operates within the Healthcare sector. The firm is primarily listed on the Bombay Stock Exchange (BSE). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
12,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

1
  • MARKETSChrysCapital takes control of Novartis India in ₹1,446 crore deal2026-07-30

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NOIN.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · 2026-07-30

    Composite-score breakdown

    Synthesis

    Business

    Novartis India Ltd (NOIN.BO) is a pharmaceutical company headquartered in India that operates within the Healthcare sector. The firm is primarily listed on the Bombay Stock Exchange (BSE). Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 5.25 and cash and equivalents of ₹490 million, indicating a robust ability to meet short-term obligations. The low debt-to-equity ratio of 0.01 suggests a conservative capital structure, with minimal reliance on long-term debt.

    Profitability metrics show a return on equity (ROE) of 12.85% and a return on assets (ROA) of 10.65%, both exceeding the typical thresholds for the pharmaceutical industry. These figures reflect efficient use of equity and assets to generate returns, aligning with the company's focus on high-margin prescription drug sales.

    Geographically, the company's revenue is concentrated in India, with no disclosed international segments. This concentration may expose the business to regulatory and macroeconomic risks specific to the Indian market, though the company's strong domestic presence and brand recognition mitigate some of these concerns.

    The company's growth trajectory is supported by a consistent revenue base of ₹3.56 billion and a net income of ₹1.01 billion. While no specific growth rates are provided, the operating cash flow of ₹745.7 million and free cash flow of ₹413.6 million suggest a stable cash-generating business model.

    Risk factors are minimal, with no immediate liquidity or dilution concerns identified. The company's low dilution risk is reinforced by the absence of recent share issuance or shelf registration activity, and the diluted shares outstanding remain unchanged from the basic shares.

    Recent filings and transcripts do not indicate any material events or strategic shifts. The company appears to be operating within a stable regulatory and market environment, with no disclosed litigation or compliance issues in the latest financial data.

    Key takeaways
    • Novartis India Ltd maintains a conservative capital structure with minimal debt and strong liquidity.
    • The company's profitability metrics (ROE and ROA) are above industry norms, indicating efficient operations.
    • Revenue is concentrated in India, which may limit diversification but leverages the company's domestic market strength.
    • No immediate liquidity or dilution risks are present, and the company's financial position is stable.
    • The company's growth is supported by strong cash flow generation, though specific growth rates are not disclosed.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 488,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $7.85B
    Net cashⓘ
    $439.4M
    Current ratioⓘ
    5.2
    Debt / equityⓘ
    0.0
    ROAⓘ
    10.7%
    ROEⓘ
    12.8%
    Cash conversionⓘ
    74.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin25,3 %Above P75
    Net Margin28,3 %Best in class
    ROE12,8 %Above P75
    D/E0,01Above median
    Cash Conv0,74Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Novartis India Ltd Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NOIN.BOCanonical
    BSE (India) · USD

    Intel & risk

    peak dispatch · 2026-07-30
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage